Cargando…
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
Autores principales: | Ohlmann, Carsten-Henning, Jäschke, Michelle, Jaehnig, Peter, Krege, Susanne, Gschwend, Jürgen, Rexer, Heidrun, Junker, Kerstin, Zillmann, Roger, Rüssel, Christoph, Hellmis, Eva, Suttmann, Henrik, Janssen, Martin, Marin, Jan, Hübner, Andreas, Mathers, Michael, Gleißner, Jochen, Scheffler, Michael, Feyerabend, Susan, Telle, Jens, Klier, Jörg, Stöckle, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638078/ https://www.ncbi.nlm.nih.gov/pubmed/37253975 http://dx.doi.org/10.1038/s41391-023-00682-2 |
Ejemplares similares
-
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2022) -
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017) -
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016) -
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017) -
Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)